Patrick Hobbins
Family Medicine · Dyer, INNPI 1518134816
Payments from drug & device makers
Across 94 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$293
- Amgen$215
- AstraZeneca$181
- Novo Nordisk$108
- Corium, LLC$100
- Lilly USA, LLC$94
- plus $608 from 21 others
What the payments were for
- Food & beverage$1,601100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 16 | $293 |
| Amgen | 12 | $215 |
| AstraZeneca | 12 | $181 |
| Novo Nordisk | 6 | $108 |
| Corium, LLC | 6 | $100 |
| Lilly USA, LLC | 5 | $94 |
| Idorsia Pharmaceuticals US Inc | 4 | $83 |
| Pfizer | 3 | $56 |
| Phathom Pharmaceuticals, Inc. | 3 | $54 |
| Exact Sciences | 3 | $53 |
| Amarin Pharma, Inc. | 3 | $41 |
| Astellas Pharma US Inc | 2 | $38 |
| GSK | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Arbor Pharmaceuticals, Inc. | 2 | $26 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Madrigal Pharmaceuticals | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Halozyme Inc | 1 | $17 |
| Adlon Therapeutics L.p. | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Merck | 1 | $12 |
| Johnson & Johnson | 1 | $11 |
How this compares
$1,601 in reported general payments places this provider in the 65th percentile of 2,709 family medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 38 | $39,047 |
| EliquisApixaban | 22 | $17,169 |
| JentaduetoLinagliptin/Metformin Hcl | 11 | $5,682 |
| Duloxetine Hcl | 33 | $1,991 |
| Pantoprazole Sodium | 42 | $1,001 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 35 | $688 |
| Atorvastatin Calcium | 72 | $613 |
| Levothyroxine Sodium | 42 | $601 |
| Tamsulosin Hcl | 19 | $510 |
| Montelukast Sodium | 15 | $459 |
| Celecoxib | 16 | $422 |
| Metoprolol Succinate | 30 | $396 |
| Bupropion XlBupropion Hcl | 12 | $384 |
| Gabapentin | 17 | $326 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $236 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $108 | $39,04738 claims |
| PfizerEliquis | $56 | $17,16922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Dyer
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.